Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297021 · ClinicalTrials.gov registry record · Phase 4
Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 141
- Enrollment target
NCT03297021: Completed Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03297021 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 141 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03297021, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 141 participants
- Enrollment target
Study Summary
The aim is to evaluate the effectiveness of three different regimens of prophylactic ondansetron on the incidence and severity of post-operative nausea and vomiting.
Primary Outcome
Nausea Scale - full scale from 1-10, with higher score indicating more symptom of nausea
Interventions
- DRUG Ondansetron 8mg
- DRUG Ondansetron 4 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 4 |
What the finished NCT03297021 record still lists
NCT03297021 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Ondansetron 8mg is the first listed.
NCT03297021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03297021 about?
NCT03297021 is a clinical study titled "Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting". The aim is to evaluate the effectiveness of three different regimens of prophylactic ondansetron on the incidence and severity of post-operative nausea and vomiting.
What is the current status of trial NCT03297021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 141 participants. The study started on 2017-10-23. Estimated completion is 2019-04-05.
What interventions are being tested in trial NCT03297021?
The interventions under investigation include: Ondansetron 8mg (DRUG), Ondansetron 4 MG (DRUG).
Who is sponsoring clinical trial NCT03297021?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03297021's enrollment target sits among peer trials
141 580th of 2000 higher than 1,420 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI